Featured Press Releases

Axion BioSystems Adds Affordable Maestro Volt™ to its Industry-Leading MEA System Lineup

Axion BioSystems Adds Affordable Maestro Volt™ to its Industry-Leading MEA System Lineup

Lykos Therapeutics Provides Update on FDA Advisory Committee Meeting for Investigational MDMA-Assisted PTSD Therapy

Lykos Therapeutics Provides Update on FDA Advisory Committee Meeting for Investigational MDMA-Assisted PTSD Therapy

  • 04 Jun 2024

Lykos Therapeutics ("Lykos"), a company dedicated to transforming mental healthcare, announced the...

Neurocrine Biosciences Presents New Post-Hoc Data from the KINECT®-HD Study, Demonstrating a Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington

Neurocrine Biosciences Presents New Post-Hoc Data from the KINECT®-HD Study, Demonstrating a Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea

The iPSCore™ platform, developed by iXCells Biotechnologies, enables the generation of highly characterized iPSC-derived human cell models

The iPSCore™ platform, developed by iXCells Biotechnologies, enables the generation of highly characterized iPSC-derived human cell models

Inoviv launches MasterKey™, a customizable platform for multiplexed protein assays

Inoviv launches MasterKey™, a customizable platform for multiplexed protein assays

Actinium Pharmaceuticals publishes Actimab-A + CLAG-M trial results for relapsed/refractory AML in Leukemia

Actinium Pharmaceuticals publishes Actimab-A + CLAG-M trial results for relapsed/refractory AML in Leukemia

Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as the First Treatment for Dry Eye Disease Associated with MGD—A Breakthrough in Ophthalmology

Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as the First Treatment for Dry Eye Disease Associated with MGD—A Breakthrough in Ophthalmology

  • Novaliq
  • 09 Jul 2025
Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418 Begins with First Patient Dosed

Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418 Begins with First Patient Dosed

  • DualityBio
  • 08 Jul 2025
With Fifth NovaSeq X Plus System in Europe, Novogene Europe Expands Sequencing Capabilities

With Fifth NovaSeq X Plus System in Europe, Novogene Europe Expands Sequencing Capabilities

  • Novogene
  • 07 Jul 2025
Novel Compound AC102 Makes Constant Ear Noise Disappear in Preclinical Model: Tinnitus Research

Novel Compound AC102 Makes Constant Ear Noise Disappear in Preclinical Model: Tinnitus Research

  • AudioCure
  • 07 Jul 2025
The European Commission grants Aurobindo Pharma approval to market the cancer drug, Dazublys

The European Commission grants Aurobindo Pharma approval to market the cancer drug, Dazublys

  • Aurobindo Pharma
  • 02 Jul 2025
Fresenius Expands Biosimilars Portfolio with Denosumab Launch in the U.S

Fresenius Expands Biosimilars Portfolio with Denosumab Launch in the U.S

  • Fresenius Kabi
  • 01 Jul 2025
Webinar: Leverage AI for Operational Excellence and Strategic Cost Management

Most Popular
July   2025
M T W T F S S
  1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30 31      

User Area

Discover

Engage with Us

© 2024 Pharmaceutical Era — A product of HISSM. All Rights Reserved.